STOP Study: Incidence and Predictors of ALT Flares in HBeAg-Negative Patients Discontinuing NA Therapy for CHB

Source: 2019 Annual Meeting of the European Association for the Study of the Liver*
Download Slideset
April 10-14, 2019; Vienna, Austria
Male sex and high HBV DNA were associated with increased flare risk in this single-center, randomized phase IV study.
Format: Microsoft PowerPoint (.ppt)
File Size: 175 KB
Released: April 15, 2019

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by:
AbbVie
Gilead Sciences

Related Content

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

CCO commentary from Anna Christina L. dela Cruz, MD, on the use of quantitative HBsAg and elastography in the management of hepatitis B

Anna Christina L. dela Cruz, MD Released: August 18, 2020

Download free expert-authored slides reviewing HBV management recommendations for specific patient populations and learn how expert faculty approach complex cases

person default Joseph Ahn, MD, MS, MBA Anna Christina L. dela Cruz, MD Released: July 21, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue